Corvus Pharmaceuticals, Inc.CRVSNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 92% recommend buying.

Consensus Rating

Buy

13 analysts·Moderate coverage

92%

Rating Distribution

Strong Buy

00%

Buy

1292%

Hold

18%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 48% higher.

Bear Case

$27.00

+26%

Consensus

$31.80

+48%

Bull Case

$42.00

+95%

Price Range13 analysts

Low

Consensus

High

$27.00

$42.00

Current Target

Current Price

$21.48

Upside to Target

$10.32

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-0.58(5 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+1801.20%

EPS—

FY2028

Rev+220.76%

EPS—

FY2029

Rev+74.15%

EPS—

Earnings Surprises

Beat rate:33%(4/12 quarters)

Avg surprise:-12.0%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 29, 2026Mizuho Securities

Corvus Pharmaceuticals price target raised to $30 from $20 at Mizuho

Target:$30.00

+46.1%from $20.54

Jan 22, 2026Jefferies

Corvus Pharmaceuticals price target raised to $42 from $13 at Jefferies

Target:$42.00

+62.8%from $25.80

Jan 21, 2026Oppenheimer

Corvus Pharmaceuticals price target raised to $32 from $15 at Oppenheimer

Target:$32.00

+42.0%from $22.54

Jan 20, 2026Barclays

Corvus Pharmaceuticals price target raised to $28 from $16 at Barclays

Target:$28.00

+30.8%from $21.41

Jan 20, 2026Mizuho Securities

Corvus Pharmaceuticals price target raised to $20 from $13 at Mizuho

Target:$20.00

+2.5%from $19.52

Jan 20, 2026H.C. Wainwright

Corvus Pharmaceuticals price target raised to $27 from $11 at H.C. Wainwright

Target:$27.00

+48.2%from $18.22

Oct 29, 2025Mizuho Securities

Corvus Pharmaceuticals price target raised to $13 from $11 at Mizuho

Target:$13.00

+72.1%from $7.55

Oct 13, 2025Barclays

Corvus Pharmaceuticals initiated with an Overweight at Barclays

Target:$16.00

+130.9%from $6.93

May 20, 2025Mizuho Securities

Corvus Pharmaceuticals price target lowered to $11 from $12 at Mizuho

Target:$11.00

+198.9%from $3.68

Nov 13, 2024Jefferies

Corvus Pharmaceuticals (CRVS) PT Raised to $13 at Jefferies

Target:$13.00

+227.5%from $3.97

Oct 22, 2024Mizuho Securities

Mizuho Upgrades Corvus Pharmaceuticals (CRVS) to Outperform

Target:$12.00

+58.7%from $7.56

Aug 18, 2023Oppenheimer

Corvus Pharmaceuticals Eyes Expansion Of Blood Cancer Therapy but Resource Limitations Pose Challenge: Oppenheimer

Target:$7.00

+219.6%from $2.19

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance